Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Business Wire IndiaNot intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant…